Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim matches the FDA label sections supplied (boxed warning/Warn. 5.1/contraindications/counseling/monitoring guidance). No contradictions or unsupported safety statements were identified.
Category Scores
Accurate Statements
Risk of thyroid C-cell tumors (including boxed warning, contraindication for MTC/MEN 2, and counseling/monitoring guidance).
Supported by Boxed Warning and Section 5.1 (thyroid C-cell tumor risk; postmarketing MTC reports insufficient for causality; contraindication in personal/family history of MTC or MEN 2; counsel on thyroid tumor symptoms; routine calcitonin/thyroid ultrasound of uncertain value). Also supported by Section 4 contraindications.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is an on-label safety message and includes the key contraindication (MTC/MEN 2) and the label’s counseling/monitoring limitations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement